Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRIMAQUINE vs ARTESUNATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.
Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.
Radical cure of Plasmodium vivax and Plasmodium ovale malaria (FDA-approved),Prophylaxis of Plasmodium vivax relapse following treatment of acute infection
Severe malaria (parenteral therapy),Uncomplicated malaria (combination therapy with other antimalarials),Off-label: Treatment of chloroquine-resistant falciparum malaria
15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.
2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.
Terminal elimination half-life of approximately 4-7 hours; in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, half-life may be prolonged due to accumulation in erythrocytes
Terminal elimination half-life of artesunate is approximately 1 hour. The active metabolite dihydroartemisinin has a half-life of 1-2 hours. This short half-life supports rapid parasite clearance in severe malaria.
Primaquine is metabolized primarily by CYP1A2 and CYP3A4; also undergoes monoamine oxidase (MAO) metabolism. Metabolites include primaquine carboxy metabolite.
Primarily hydrolyzed in the stomach and in plasma by esterases to dihydroartemisinin (DHA), the active metabolite. DHA undergoes glucuronidation via UGT1A9 and UGT2B7.
Primarily renal (60-65% as unchanged drug and metabolites); small amounts in feces (<5%)
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% as unchanged drug. Biliary/fecal elimination is minimal. ~80% of the dose is recovered in urine as metabolites, mainly dihydroartemisinin.
Approximately 90-95% bound to plasma proteins, primarily to albumin
Artemisinin derivatives: ~93% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
Apparent volume of distribution (Vd) approximately 2.5-3.5 L/kg, indicating extensive tissue distribution, including high concentrations in erythrocytes and liver, which is relevant for anti-relapse activity
Vd approximately 0.6-0.8 L/kg, indicating distribution into total body water. Higher Vd in severe malaria due to increased capillary permeability.
Oral bioavailability is approximately 96%, with peak plasma concentrations reached within 1-3 hours
Oral: ~40% (range 20-50%) due to first-pass metabolism. Rectal: ~40-60%. IV: 100%.
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment due to potential accumulation.
No dose adjustment required for any degree of renal impairment.
Contraindicated in severe hepatic impairment; use with caution in mild-to-moderate impairment, reduce dose by 50% in Child-Pugh B, avoid in Child-Pugh C.
No dose adjustment required for Child-Pugh A or B; caution in Child-Pugh C due to limited data.
0.3 mg/kg (base) orally once daily for 14 days; maximum 15 mg/day.
2.4 mg/kg IV at 0, 12, 24, and 48 hours; weight-based (minimum 2.4 mg/kg per dose).
No specific dose adjustment, but monitor for hemolytic effects due to age-related decline in G6PD activity.
No specific dose adjustment; use same dosing as adults with monitoring for adverse effects.
Primaquine can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Screen all patients for G6PD deficiency before prescribing.
None.
Hemolytic anemia in G6PD deficiency – screen and monitor,Methemoglobinemia – monitor for signs especially in infants and G6PD-deficient patients,QT interval prolongation – use with caution with other QT-prolonging drugs,Hematologic toxicity – monitor CBC in prolonged therapy
Hemolysis: Cases of delayed hemolytic anemia have been reported, especially in patients with high parasitemia.,Cardiotoxicity: Theoretical risk of QT prolongation with co-administration of other QT-prolonging drugs.,Hypersensitivity: Severe allergic reactions (e.g., anaphylaxis) have occurred.
G6PD deficiency (absolute),Concurrent use of quinacrine (due to increased toxicity),Pregnancy (safe alternative not established; risk of hemolysis in G6PD-deficient fetus),Lactation if infant is G6PD deficient
Hypersensitivity to artesunate, any artemisinin derivative, or any component of the formulation.,Pregnancy: Not recommended in first trimester unless life-threatening; avoid in second/third trimester if safer alternatives available.,Breastfeeding: Safety not established; discontinue breast-feeding or avoid drug.
Take with food to reduce gastrointestinal irritation. No specific food restrictions, but avoid alcohol as it may increase risk of adverse effects.
No known significant food interactions. However, avoid grapefruit and grapefruit juice as they may alter drug metabolism (CYP2A6 inhibition). Maintain adequate hydration and nutrition to support recovery.
Primaquine crosses the placenta. In the first trimester, fetal G6PD deficiency increases risk of hemolytic anemia. Second and third trimesters: potential for fetal methemoglobinemia. Risk of hemolysis in G6PD-deficient fetuses; contraindicated in pregnancy except for severe malaria treatment when no alternatives exist.
Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benefit of treating life-threatening malaria generally outweighs risks, as untreated malaria poses significant fetal risks. However, the drug should be used with caution and only when clearly needed.
Primaquine is excreted into breast milk in small amounts. M/P ratio not established. Risk of hemolysis in G6PD-deficient infants. Avoid breastfeeding in women with infant G6PD deficiency; use caution.
Artesunate is excreted into breast milk in small amounts. The M/P ratio is not well-established. While the American Academy of Pediatrics considers artesunate compatible with breastfeeding, caution is advised, especially in nursing preterm or jaundiced infants. The benefits of breastfeeding and the necessity of maternal treatment should be weighed.
Pregnancy reduces primaquine exposure via increased clearance; however, due to teratogenicity and hemolytic risk, dosing adjustments are not recommended; alternative antimalarials preferred.
No dose adjustment is required for artesunate during pregnancy based on pharmacokinetic changes. However, intravenous artesunate is the recommended treatment for severe malaria in the second and third trimesters. Oral artesunate may be used for uncomplicated malaria, but caution is advised in the first trimester due to teratogenicity.
Primaquine is the only agent active against hypnozoites of Plasmodium vivax and P. ovale, preventing relapse. Screen for G6PD deficiency before use; hemolysis risk. Administer with food to reduce GI upset.
Artesunate is the first-line therapy for severe malaria (WHO recommendation). Administer IV or IM; IV dose is 2.4 mg/kg at 0, 12, and 24 hours then daily. Monitor for hypoglycemia and delayed hemolytic anemia (post-artesunate hemolysis). Not recommended for uncomplicated malaria due to risk of resistance. Artesunate is rapidly acting with a short half-life; always combine with a partner drug (e.g., artemether-lumefantrine) for complete cure. Do not use in first trimester of pregnancy unless life-threatening.
Take with food to decrease stomach upset.,Report any signs of hemolysis: dark urine, yellow skin/eyes, fatigue.,Complete full course even if symptoms improve.,Avoid concurrent use with other drugs that cause hemolysis.,Inform your doctor of any history of favism or G6PD deficiency.
Take this medication exactly as prescribed; do not stop early even if you feel better.,You may experience temporary side effects such as dizziness, nausea, or fatigue; report any severe reactions.,This drug is used for severe malaria; you will likely be hospitalized for close monitoring.,Watch for signs of low blood sugar (sweating, confusion, rapid heartbeat) and report immediately.,Inform your healthcare provider about all medications you are taking, especially blood thinners or anti-seizure drugs.,Complete the full course of treatment, including any follow-up medications to prevent recurrence.
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
"Nicotine, a known inducer of cytochrome P450 (CYP) enzymes, particularly CYP1A2 and possibly CYP2A6, may increase the hepatic metabolism of artesunate to its active metabolite dihydroartemisinin. This enhanced clearance can lead to subtherapeutic plasma concentrations of dihydroartemisinin, reducing the antimalarial efficacy of artesunate and potentially increasing the risk of treatment failure and the development of drug resistance."
"Amiodarone, a potent CYP3A4 and CYP2B6 inhibitor, can significantly reduce the systemic exposure of dihydroartemisinin, the active metabolite of artesunate. This occurs through inhibition of cytochrome P450 enzymes responsible for the conversion of artesunate to its active form, leading to decreased antimalarial efficacy. Clinically, this interaction may result in treatment failure or recrudescence of malaria when artesunate is co-administered with amiodarone."
"The coadministration of buprenorphine, a partial mu-opioid receptor agonist, with artesunate may reduce the systemic exposure of dihydroartemisinin (DHA), the primary active metabolite of artesunate, thereby decreasing antimalarial efficacy. This interaction is believed to occur through buprenorphine-mediated induction of cytochrome P450 (CYP) enzymes responsible for artesunate metabolism, leading to enhanced clearance and subtherapeutic concentration of DHA. Clinically, this could result in delayed parasite clearance and increased risk of treatment failure in malaria patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRIMAQUINE vs ARTESUNATE, answered by our medical review team.
PRIMAQUINE is a Antimalarial that works by Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.. ARTESUNATE is a Antimalarial that works by Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRIMAQUINE and ARTESUNATE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRIMAQUINE is: 15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.. The standard adult dose of ARTESUNATE is: 2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRIMAQUINE and ARTESUNATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRIMAQUINE is classified as Category D/X. Primaquine crosses the placenta. In the first trimester, fetal G6PD deficiency increases risk of hemolytic anemia. Second and third trimesters: potential for fetal methemoglobinemi. ARTESUNATE is classified as Category C. Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benef. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.